TMC435 + darunavir + ritonavir

**TMC435 + darunavir + ritonavir** is a combination of three antiviral agents potentially investigated for the treatment of HIV-1 infection and coinfection scenarios with hepatitis C virus (HCV). TMC435 (also known as simeprevir) is a direct-acting antiviral, specifically an HCV NS3/4A protease inhibitor. Darunavir is an HIV-1 protease inhibitor, and ritonavir is used primarily as a pharmacokinetic booster to increase darunavir's plasma levels. - **Mechanisms**: - TMC435: Inhibits HCV NS3/4A protease, blocking HCV polyprotein processing and viral replication. - Darunavir: Inhibits HIV-1 protease, preventing viral polyprotein cleavage required for mature virus production. - Ritonavir: Inhibits CYP3A4 (mainly), boosting plasma concentrations of darunavir. - **Indications**: The combination may be considered in HIV/HCV coinfection or other investigative regimens. Darunavir + ritonavir is approved for HIV-1; TMC435 (simeprevir) is approved for HCV genotype 1 and 4.

Other names

simeprevir + darunavir + ritonavir